FDA told Calroy Health Sciences that website claims make its Arterosil supplement an unapproved drug for treating disease.
What happened
FDA reviewed www.arterosil.com in October 2022 and found the company takes orders there for Arterosil. FDA said website claims about plaque, diabetes, stroke, hypertension, and neuropathy show Arterosil is intended to cure, mitigate, treat, or prevent disease. FDA calls it a "new drug" (not generally recognized as safe and effective for those uses and not FDA-approved) and says it is misbranded because it lacks adequate directions for use.
What FDA found
FDA treats Arterosil as a drug because website claims say it can treat or prevent diseases such as heart disease, diabetes, stroke, hypertension, and neuropathy.
section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 321(g)(1)(B)]Arterosil is not generally recognized as safe and effective for those claimed disease uses, so FDA classifies it as a new drug.
section 201(p) of the Act [21 U.S.C. 321(p)]The company offered Arterosil for interstate commerce for drug uses without the required FDA approval.
sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]Arterosil lacks adequate directions for use because its claimed diseases cannot be safely self-diagnosed or self-treated without a licensed practitioner.
section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]The company introduced or delivered a misbranded drug into interstate commerce.
section 301(a) of the Act [21 U.S.C. 331(a)]
What FDA wants
FDA asks Calroy to notify it in writing within 15 working days of the steps taken to address the violations, including how it will prevent recurrence and related documents. If corrections cannot be finished in that time, the company must explain the delay and give a completion date.
Who should pay attention
- dietary supplement brands that make disease claims
- marketing and compliance teams for supplement websites
- online sellers of supplements
This is a summary. Read the original letter on fda.gov.